Clinical Experience with Perampanel in Intractable Focal Epilepsy Over 12 Months of Follow-Up
Soo Yeon Kim, Woo Joong Kim, Hyuna Kim, Sun Ah Choi, Byung Chan Lim, Jong-Hee Chae, Ki Joong Kim
J Epilepsy Res. 2018;8(2):61-65. Published online 2018 Jul 25 DOI: https://doi.org/10.14581/jer.18010
Citations to this article as recorded by 
Efficacy and Safety of adjunctive Perampanel in a prospective, real‐world, Phase IV study in Indian patients aged ≥12 years for Treatment of focal‐onset Epilepsy: Study 508
Sangeeta Ravat, Anshu Rohatgi, Rahul Kulkarni, Shaik A. Jabeen, Balaji Patil, Amitabh Dash, Manoj Malhotra
Epilepsia Open.2024;[Epub] CrossRef
Efficacy and tolerability of perampanel in patients with seizures in real-world clinical practice: A systematic review and meta-analysis
Liyan Hou, Jingjing Yang, Xuan Zhang, Na Li, Sheng Li, Lei Zhang, Jie Zhao, Qingshan Wang
Frontiers in Pharmacology.2023;[Epub] CrossRef
Evaluation of persistence and healthcare utilization in patients treated with anti-seizure medications as add-on therapy: A nationwide cohort study in South Korea
Ji Woong Lee, Jung-Ae Kim, Min Young Kim, Sang Kun Lee
Epilepsy & Behavior.2022; 126: 108459. CrossRef
A post-approval observational study to evaluate the safety and tolerability of perampanel as an add-on therapy in adolescent, adult, and elderly patients with epilepsy
Melissa Maguire, Elinor Ben-Menachem, Anna Patten, Manoj Malhotra, Leock Y. Ngo
Epilepsy & Behavior.2022; 126: 108483. CrossRef
Effectiveness and tolerability of adjunctive perampanel in pediatric patients (aged 4–12 years) with refractory epilepsy: An observational study
Si-Jia Chu, Yan Li, Ji-Hong Tang
Medicine.2022; 101(45): e31408. CrossRef
Perampanel effectiveness and safety as early add-on treatment for focal-onset seizures: PEREAGAL study
X. Rodríguez-Osorio, T. Lema-Facal, E. Rubio-Nazábal, M.D. Castro-Vilanova, A. Pato-Pato, J. Abella-Corral, E. Corredera, A. López-Ferreiro, A. Puy-Núñez, F.J. López-González
Epilepsy Research.2021; 172: 106570. CrossRef
Comparative 12-month retention rate, effectiveness and tolerability of perampanel when used as a first add-on or a late add-on treatment in patients with focal epilepsies: The COM-PER study
Nuno Canas, Catarina Félix, Vanessa Silva, Ana Arraiolos, Fernando Fernandez-Llimos
Seizure.2021; 86: 109. CrossRef
Efficacy and tolerability of perampanel as adjunctive treatment of focal and generalized tonic-clonic epileptic seizures in children over 4 years of age
E.D. Belousova
Zhurnal nevrologii i psikhiatrii im. S.S. Korsakov.2021; 121(3): 116. CrossRef
Effectiveness and safety of perampanel as early add-on treatment in patients with epilepsy and focal seizures in the routine clinical practice: Spain prospective study (PERADON)
Javier Abril Jaramillo, José Carlos Estévez María, Juan Miguel Girón Úbeda, Óscar Vega López, María Elena Calzado Rivas, Hernando Pérez Díaz, Guillermina García Martín, Elena Vila Herrero, M. Chamorro-Muñoz, F. Vázquez, C. De la Fuente, L. Redondo, N. Pel
Epilepsy & Behavior.2020; 102: 106655. CrossRef
Relationship between plasma concentrations and clinical effects of perampanel: A prospective observational study
Manuela Contin, Federica Pondrelli, Lorenzo Muccioli, Susan Mohamed, Margherita Santucci, Lorenzo Ferri, Laura Licchetta, Paolo Tinuper, Francesca Bisulli, Irene Ambrosetti, Antonella Boni, Tullio Messana, Roberto Michelucci, Barbara Mostacci, Antonia Par
Epilepsy & Behavior.2020; 112: 107385. CrossRef
LncRNA ILF3-AS1 mediated the occurrence of epilepsy through suppressing hippocampal miR-212 expression
Xiaodong Cai, Ling Long, Chao Zeng, Guanzhong Ni, Yangyang Meng, Qiang Guo, Ziyi Chen, Zhong Li
Aging.2020; 12(9): 8413. CrossRef